Alembic Pharmaceuticals Q1FY18 consolidated net profit declines 39 per cent yoy
Alembic Pharmaceuticals consolidated revenue for the quarter came in at Rs. 648 crore, registering 12% yoy decline.
This was driven by 21% yoy decrease in revenue from India formulation business. It has also registered de-growth of 8.7% yoy in its international formulation business.
EBITDA for the quarter fell by 35.7% yoy to Rs. 101 crore with a corresponding margin contraction of 571 bps. EBITDA margin for the quarter stood at 15.6%. This margin contraction was driven by increase in purchase of stock in trade and employee benefit expenses by 50% yoy and 18% yoy respectively.
The PAT for the quarter came in at Rs. 63 crore, yoy decline of 39%.
During the quarter, Q1FY18, company has received 6 ANDA (Abbreviated New Drug Application), cumulative ANDA approvals at 58.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd